Giant-cell Tumor of Bone: Treatment Options and Role of Denosumab

Overview

Journal Biologics

Date 2015 Jul 24

PMID 26203221

Citations 28

Authors

Arun S Singh

Neal S Chawla

Sant P Chawla

Affiliations

Soon will be listed here.

Abstract

Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-κB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.

Citing Articles

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?.

de la Calva C, Angulo M, Gonzalez-Rojo P, Peiro A, Machado P, Cebrian J Cancer Rep (Hoboken). 2025; 8(1):e70117.

PMID: 39797695 PMC: 11726647. DOI: 10.1002/cnr2.70117.

RANKL, OPG, and RUNX2 expression and epigenetic modifications in giant cell tumour of bone in 32 patients.

Amri R, Chelly A, Ayedi M, Rebaii M, Aifa S, Masmoudi S Bone Joint Res. 2024; 13(2):83-90.

PMID: 38368904 PMC: 10875390. DOI: 10.1302/2046-3758.132.BJR-2023-0023.R2.

Giant Cell Tumour of Bone: A Comprehensive Review of Pathogenesis, Diagnosis, and Treatment.

Jha Y, Chaudhary K Cureus. 2023; 15(10):e46945.

PMID: 38022126 PMC: 10640696. DOI: 10.7759/cureus.46945.

Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report.

Klienkoff P, Weingertner N, Geyer L, Gros C, Kurtz J, Bornert F Int J Surg Case Rep. 2023; 112:108980.

PMID: 37913666 PMC: 10667875. DOI: 10.1016/j.ijscr.2023.108980.

Partial sternectomy with reconstruction of a giant cell tumor of the sternum, a case report, Saudi, Arabia.

Eldaabossi S, Al-Ghoneimy Y, Antar A, Lotfy E, Aljawad H, Abish Y J Cardiothorac Surg. 2023; 18(1):296.

PMID: 37848912 PMC: 10580503. DOI: 10.1186/s13019-023-02404-0.

References

Kivioja A, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer H . Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008; 79(1):86-93. DOI: 10.1080/17453670710014815. View

Byers V, Levin A, Johnston J, Hackett A . Quantitative immunofluorescence studies of the tumor antigen-bearing cell in giant cell tumor of bone and osteogenic sarcoma. Cancer Res. 1975; 35(9):2520-31. View

Gouin F, Rochwerger A, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F . Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer. 2014; 50(14):2425-31. DOI: 10.1016/j.ejca.2014.06.003. View

Tse L, Wong K, Kumta S, Huang L, Chow T, Griffith J . Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2007; 42(1):68-73. DOI: 10.1016/j.bone.2007.08.038. View

Campanacci M, Baldini N, Boriani S, Sudanese A . Giant-cell tumor of bone. J Bone Joint Surg Am. 1987; 69(1):106-14. View

Cheng Y, Huang L, Lee K, Xu J, Zheng M, Kumta S . Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004; 75(1):71-7. DOI: 10.1007/s00223-004-0120-2. View

Rock M, Sim F, Unni K, Witrak G, Frassica F, Schray M . Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg Am. 1986; 68(7):1073-9. View

Cowan R, Singh G, Ghert M . PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone. J Orthop Res. 2011; 30(6):877-84. DOI: 10.1002/jor.22020. View

George S, Merriam P, Maki R, Van Den Abbeele A, Yap J, Akhurst T . Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009; 27(19):3154-60. PMC: 2716937. DOI: 10.1200/JCO.2008.20.9890. View

10.

Anderson D, Maraskovsky E, Billingsley W, Dougall W, Tometsko M, Roux E . A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997; 390(6656):175-9. DOI: 10.1038/36593. View

11.

Branstetter D, Nelson S, Manivel J, Blay J, Chawla S, Thomas D . Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012; 18(16):4415-24. DOI: 10.1158/1078-0432.CCR-12-0578. View

12.

Lin P, Guzel V, Moura M, Wallace S, Benjamin R, Weber K . Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer. 2002; 95(6):1317-25. DOI: 10.1002/cncr.10803. View

13.

Martin-Broto J, Cleeland C, Glare P, Engellau J, Skubitz K, Blum R . Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol. 2014; 53(9):1173-9. DOI: 10.3109/0284186X.2014.910313. View

14.

Bardi G, Pandis N, Mandahl N, Heim S, Sfikas K, Willen H . Chromosomal abnormalities in giant cell tumors of bone. Cancer Genet Cytogenet. 1991; 57(2):161-7. DOI: 10.1016/0165-4608(91)90147-m. View

15.

Karras N, Polgreen L, Ogilvie C, Manivel J, Skubitz K, Lipsitz E . Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol. 2013; 31(12):e200-2. PMC: 4878007. DOI: 10.1200/JCO.2012.46.4255. View

16.

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

17.

Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R . Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer. 2010; 10:462. PMC: 2940802. DOI: 10.1186/1471-2407-10-462. View

18.

Goldring S, Roelke M, Petrison K, Bhan A . Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987; 79(2):483-91. PMC: 424109. DOI: 10.1172/JCI112838. View

19.

Lacey D, Boyle W, Simonet W, Kostenuik P, Dougall W, Sullivan J . Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11(5):401-19. DOI: 10.1038/nrd3705. View

20.

Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J . Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010; 11(3):275-80. DOI: 10.1016/S1470-2045(10)70010-3. View